Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

2025年1月27日， Madrigal（MDGL）披露4笔公司内部人交易情况。董事Sibold William John于2025年1月24日卖出1584股。

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical company whose stock has gained nearly 12% in the past week, recently sold 347 ...

The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted ...